In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 275-281

  Polak, Sebastian ^a,b   Wiśniowska, Barbara ^a   Fijorek, Kamil ^c   Glinka, Anna ^a   Mendyk, Aleksander ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b CERTARA UK LIMITED   (United Kingdom)

^c CRACOW UNIVERSITY OF ECONOMICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; DRUG INDUSTRY; DRUG SAFETY; HEART PROARRHYTHMIA; HUMAN; IN VITRO IN VIVO EXTRAPOLATION; MATHEMATICAL MODEL; POPULATION RESEARCH; PREDICTION; REVIEW; ANIMAL; CARDIOTOXICITY; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; ECONOMICS; HEART ARRHYTHMIA; PATHOPHYSIOLOGY; PROCEDURES; THEORETICAL MODEL; TOXICITY TESTING; TRANSLATIONAL RESEARCH;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOTOXICITY; COST-BENEFIT ANALYSIS; HUMANS; MODELS, THEORETICAL; TOXICITY TESTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84896405843     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.10.009     Document Type: Review

References (66)

1. D. Rottenkolber et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations Pharmacoepidemiol. Drug. Saf. 20 2011 626 634
2. E.C. Davies et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes PLoS One 4 2009 1 7
3. D. Justo, and D. Zeltser Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports Mycoses 49 2006 463 470 (Pubitemid 44511096)
4. J.A. DiMasi et al. Trends in risks associated with new drug development: success rates for investigational drugs Clin. Pharmacol. Ther. 87 2010 272 277
5. W.S. Redfern et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle Toxicologist 114 2010 1081
6. J.P. Piccini et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative Am. Heart. J. 158 2009 317 326
7. J.L. Stevens, and T.K. Baker The future of drug safety testing: expanding the view and narrowing the focus Drug Discov. Today 14 2009 162 167
8. X. Yajuan et al. A comparison of the performance and application differences between manual and automated patch-clamp techniques Curr. Chem. Genomics 6 2012 87 92
9. R. Towart et al. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods 60 2009 1 10
10. S.A. Niederer et al. A meta-analysis of cardiac electrophysiology computational models Exp. Physiol. 94 2009 486 495
11. E. Vigmond et al. Towards predictive modelling of the electrophysiology of the heart Exp. Physiol. 94 2009 563 577
12. H.J. Witchel et al. Psychotropic drugs, cardiac arrhythmia, and sudden death J. Clin. Psychopharmacol. 23 2003 58 77 (Pubitemid 36164427)
13. R.L. Martin et al. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block J. Cardiovasc. Pharmacol. 43 2004 369 379 (Pubitemid 38270603)
14. P. Hoffmann, and B. Warner Are hERG channel inhibition and QT interval prolongation all there is in drug induced torsadogenesis? A review of emerging trends J. Pharmacol. Toxicol. Methods 53 2006 87 105
15. G.R. Mirams et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk Cardiovasc. Res. 91 2011 53 61
16. A.E. Lacerda et al. Alfuzosin delays cardiac repolarization by a novel mechanism J. Pharmacol. Exp. Ther. 324 2008 427 433 (Pubitemid 351185830)
17. S. Rajamani et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine Br. J. Pharmacol. 149 2006 481 489 (Pubitemid 44658508)
18. Y.A. Kuryshev et al. Pentamidine-induced long QT syndrome and block of hERG trafficking J. Pharmacol. Exp. Ther. 312 2005 316 323 (Pubitemid 40096484)
19. W.S. Redfern et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovas. Res. 58 2003 32 45 (Pubitemid 36351620)
20. J. Kramer et al. MICE models: superior to the HERG model in predicting Torsade de pointes Scientific Reports 3 2013 2100 10.1038/srep02100
21. A. Rostami-Hodjegan, and G.T. Tucker Simulation and prediction of in vivo drug metabolism in human populations from in vitro data Nat. Rev. Drug Discov. 6 2007 140 148 (Pubitemid 46745341)
22. T.V. Pham., and M.R. Rosen Sex, hormones, and repolarization Cardiovasc. Res. 53 2002 740 751 (Pubitemid 34175265)
23. T. Sedlak et al. Sex hormones and the QT interval: a review J. Womens Health 21 2012 933 941
24. E.P. Harrigan et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition J. Clin. Psychopharmacol. 24 2004 62 69 (Pubitemid 38134167)
25. K.P. Letsas et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors Clin. Res. Cardiol. 98 2009 208 212
26. M.J. Boyce et al. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study Br. J. Clin. Pharmacol. 73 2012 411 421
27. B.R. Rao, and D. Rambhau Diurnal oscillations in the serum and salivary levels of quinidine Arzneimittelforschung. 45 1995 681 683
28. R.B. Smith et al. Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration J. Clin. Pharmacol. 26 1986 120 124 (Pubitemid 16134437)
29. J. Yang et al. The effects of dose staggering on metabolic drug-drug interactions Eur. J. Pharm. Sci. 20 2003 223 232 (Pubitemid 37205216)
30. P. Svorc et al. Chronobiological aspects of ketamine/xylazine anesthesia impact on the cardiovascular system, the acid-base balance, ions and autonomic nervous system in Wistar rats Acta Physiol. 206 Suppl. 693 2012 Abstr. P91
31. B. Lemmer et al. Chronopharmacokinetics and cardiovascular effects of nifedipine Chronobiol. Int. 8 1991 485 494
32. T.F. Blaschke et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories Annu. Rev. Pharmacol. Toxicol. 52 2012 275 301
33. H. Kastrissios, and T.F. Blaschke Medication compliance as a feature in drug development Annu. Rev. Pharmacol. Toxicol. 37 1997 451 475 (Pubitemid 27238884)
34. O.H. Bosma et al. Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors J. Heart Lung Transplant 30 2011 1275 1280
35. A.V. Guanzon, and M.A. Crouch Phase IV trial evaluating the effectiveness and safety of dofetilide Ann. Pharmacother. 38 2004 1142 1147 (Pubitemid 38802149)
36. H.L. Lummis et al. Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study BMC Neurol. 8 2008 25
37. A. Rostami-Hodjegan Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology Clin. Pharmacol. Ther. 92 2012 50 61
38. G.G. Gibson, and A. Rostami-Hodjegan Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE) Xenobiotica 37 2007 1013 1014
39. K.R. Yeo et al. Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach Expert Rev. Clin. Pharmacol. 6 2013 143 157
40. A.J. Atkinson Jr., and P.M. Lyster Systems clinical pharmacology Clin. Pharmacol. Ther. 88 2010 3 6
41. T.N. Johnson et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance Clin. Pharmacokinet. 49 2010 189 206
42. K.R. Yeo et al. Modeling and predicting drug pharmacokinetics in patients with renal impairment Expert Rev. Clin. Pharmacol. 4 2011 261 274
43. S. Polak In vitro to human in vivo translation-pharmacokinetics and pharmacodynamics of quinidine ALTEX 30 2013 309 318
44. G.R. Mirams et al. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing Br. J. Pharmacol. 167 2012 932 945
45. J.D. Moreno et al. A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms Sci. Transl. Med. 3 2011 98ra83
46. N. Zemzemi et al. Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials Br. J. Pharmacol. 168 2013 718 733
47. J. Cieniawa et al. Modeling gender effects on electrical activity of single ventricular myocytes Comput. Biol. Med. 43 2013 1063 1072
48. S. Polak et al. Virtual population generator for human cardiomyocytes parameters. In silico drug cardiotoxicity assessment Toxicol. Mech. Methods 22 2012 31 40
49. S. Polak, and K. Fijorek Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment - analysis of the age - cardiomyocytes electric capacitance dependence J. Cardiovasc. Transl. Res. 5 2012 321 332
50. K. Fijorek et al. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study Theor. Biol. Med. Model. 10 2013 7
51. C.M. Ambrosi et al. Gender differences in electrophysiological gene expression in failing and non-failing human hearts PLoS One 8 2013 e54635
52. J. Walmsley et al. mRNA expression levels in failing human hearts predict cellular electrophysiological remodeling: a population based simulation study PLoS One 8 2013 e56359
53. O.J. Britton et al. Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology PNAS 2013 10.1073/pnas.1304382110
54. N. Stockbridge et al. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 36 2013 167 182
55. K.R. Chi Revolution dawning in cardiotoxicity testing Nat. Rev. Drug Discov. 12 2013 565 567
56. F. Vadakkumpadan et al. Patient-specific modeling of the heart: estimation of ventricular fiber orientations J. Vis. Exp. 2013 50125 10.3791/50125
57. A.F. James et al. Recent advances in understanding sex differences in cardiac repolarization Prog. Biophys. Mol. Biol. 94 2007 265 319 (Pubitemid 46766581)
58. S.P. Etheridge et al. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations J. Am. Coll. Cardiol. 42 2003 1777 1782 (Pubitemid 37433657)
59. A. Covic et al. Haemodialysis increases QT(c) interval but not QT(c) dispersion in ESRD patients without manifest cardiac disease Nephrol. Dial. Transplant. 17 2002 2170 2177 (Pubitemid 35446674)
60. A. Pacifico, and P.D. Henry Structural pathways and prevention of heart failure and sudden death J. Cardiovasc. Electrophysiol. 14 2003 764 775 (Pubitemid 36849617)
61. X. Jouven et al. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy Heart 88 2002 153 157 (Pubitemid 34787768)
62. C. Antzelevitch M cells in the human heart Circ. Res. 106 2010 815 817
63. R.I. Harris, and S.E. Steare A meta-analysis of ECG data from healthy male volunteers: diurnal and intra-subject variability, and implications for planning ECG assessments and statistical analysis in clinical pharmacology studies Heart 89 2003 882 886
64. M. Malik et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval Heart 87 2002 220 228 (Pubitemid 34177674)
65. L. Crotti et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome Circulation 112 2005 1251 1258 (Pubitemid 41266719)
66. M.J. McPate et al. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 C Biochem. Biophys. Res. Commun. 334 2005 441 449 (Pubitemid 40982387)